Viveve Medical Inc (VIVE) Gets a Buy Rating from Mizuho Securities

By Ryan Adsit

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Viveve Medical Inc (VIVEResearch Report), with a price target of $4. The company’s shares closed yesterday at $0.87, equals to its 52-week low of $0.87.

Yang commented:

“We expect these data readouts and milestone events will be the key drivers of VIVE shares in 2019/2020.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.2% and a 50.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.

Viveve Medical Inc has an analyst consensus of Strong Buy, with a price target consensus of $3.75, representing a 328.8% upside. In a report issued on March 5, Maxim Group also reiterated a Buy rating on the stock with a $6 price target.

See today’s analyst top recommended stocks >>

Based on Viveve Medical Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $12.3 million. In comparison, last year the company had a GAAP net loss of $10.22 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Viveve Medical, Inc. engages in the provision of health products. Its activities include development and distribution of women’s health solutions. Its products include non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue. The company was founded on March 3, 1987 and is headquartered Englewood, CO.